Venture&Growth Archives - Gilde Healthcare

latest news
Venture&Growth

Gilde Healthcare co-leads oversubscribed €54 Million Series B round of Argá Medtech

Argá Medtech, a company developing a next-generation cardiac ablation system for treating cardiac arrhythmias, including atrial fibrillation (AF), announced it closed a €54M oversubscribed Series B raise co-led by Gilde Healthcare with existing investors, Advent Life Sciences (U.K.) and Earlybird Venture Capital (Germany), as well as an undisclosed strategic investor. The financing enables Argá Medtech to advance the development of...
February 28, 2024

Gilde Healthcare leads $125 Million Equity Financing of Mainstay Medical

test Funding to accelerate commercial growth and expand clinical and health economic evidence for ReActiv8® Restorative NeuromodulationTM System Mainstay Medical Holdings plc today announced an equity financing in which it will receive gross proceeds of US$125 million. Mainstay intends to use the funds to support the company’s continued commercial growth of ReActiv8® Restorative Neurostimulation in the […]

Gilde portfolio company LAVA Therapeutics announces collaboration with Merck & Co

test LAVA Therapeutics N.V. (Nasdaq: LVTX), today announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA to evaluate its anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in combination with LAVA-1207, a Gammabody® designed to target the prostate-specific membrane antigen (PSMA) to trigger the potent and preferential killing […]

Amphista Therapeutics announces in vivo efficacy and CNS activity of its protein degraders

First demonstration of efficacy in disease-relevant in vivo models for an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader Deep degradation of target protein is achieved in a rapid, sustained, and highly selective manner Successful achievement of efficient CNS delivery for multiple degraders and demonstration of significant...

James Leech Joins Moximed as Chief Financial and Strategy Officer

Leech brings expertise in financing and scaling growth-stage medtech companies. Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that James Leech has joined the company as Chief Financial and Strategy Officer. “James adds...

Gilde Healthcare company AM-Pharma initiates Phase 2 trial of Ilofotase alfa for cardiac surgery-associated renal damage

Trial will evaluate ilofotase alfa as a treatment to prevent renal damage in at-risk patients following open heart surgery Ilofotase alfa’s clinical record of renal protective effects supports therapeutic potential in underserved and high-need indication AM-Pharma B.V. today announced that the first patients have been treated in...

Gilde Healthcare announces Calypso to be acquired by Novartis for up to USD 425M

The acquisition of Calypso gives Novartis full rights to CALY-002, a pipeline-in-a-drug with potential in dermatology, gastro-intestinal and rheumatology indications Calypso is a European biotech translating Interleukin-15 biology into medical breakthroughs by developing CALY-002, an anti-IL-15 monoclonal antibody, for an array of auto-immune indications Gilde Healthcare acted...

Gilde Healthcare company Nalu Medical Inc. raises $65 million equity financing to advance treatment for chronic neuropathic pain

Carlsbad, California (USA) – Nalu Medical Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-opioid solutions for chronic neuropathic pain, announced today the closing of a $65 million equity financing. The round was led by a new investor, Novo Holdings. Also participating in the...

Gilde Healthcare’s Ablative Solutions, Inc. meets Primary Endpoint in Pivotal Trial for Hypertension

Ablative Solutions, Inc., today announced that the TARGET BP I Pivotal Trial evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit met its primary endpoint, showing a statistically significant difference in 24-hour Ambulatory Blood Pressure between treatment and sham procedure at 3 months. The TARGET BP I...
Loading...
These were all messages
24d90803cb